Clinical trials: ADD/ADHD
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials
This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD
- Trial name
- NCT00151957
- Testing
- Methylphenidate Transdermal System
- Volunteers
- 450 people
- Sponsor
- Noven Therapeutics
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Attention-deficit/Hyperactivity Disorder
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond…
- Trial name
- NCT01081145
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 81 sites in United States, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Shire
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD).
- Trial name
- NCT00192023
- Testing
- atomoxetine 0.5 mg/kg/day, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day
- Where
- 12 sites in Italy
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children
Principal focus is to evaluate the effects of omega 3 fatty acids supplementation on the ADHD children's behaviour during 12 weeks on two years.
- Trial name
- NCT00770627
- Testing
- Omega 3 caps
- Where
- 2 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laboratoires URGO
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
ADHD
Assessing a Wearable Digital Therapy for Youth With ADHD
The purpose of this study is to evaluate and compare three different investigational wearable digital interventions to determine if they are helpful for improving symptoms and functioning in children diagnosed with…
- Trial name
- NCT05710965
- Testing
- FRx-001, FRx-003, FRx-004
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Revibe Technologies